[目的]探讨拉贝洛尔联合依诺肝素治疗妊娠期高血压疾病患者的临床疗效.[方法]选取2017年6月至2018年6月在本院诊治的102例妊娠期高血压疾病患者,按照随机数表法分为观察组和对照组.对照组患者口服拉贝洛尔片治疗,观察组在对照组基础上加用依诺肝素治疗.比较两组患者治疗前后血压、24 h尿蛋白量、血脂指标水平及临床疗效、用药期间不良反应发生率和不良妊娠结局.[结果]观察组总有效率为94 .1%(48／51) ,显著高于对照组的78 .4%(40／51) ,其差异有统计学意义(χ2 ＝7 .318 ,P ＜0 .05) .治疗前,两组患者血压、24 h尿蛋白量比较差异无统计学意义( P ＞0 .05) ;治疗后,两组上述指标均较治疗前显著下降( P ＜0 .05) ,且观察组下降更为明显( P ＜0 .05).治疗前,两组血脂水平比较差异无统计学意义( P ＞0 .05) ;治疗后,两组低密度脂蛋白胆固醇(LDL‐C)、总胆固醇(TC)、三酰甘油(TG)均显著低于治疗前,高密度脂蛋白胆固醇(HDL‐C)水平显著高于治疗前,且观察组显著优于对照组( P ＜0 .05) .与对照组比较,观察组早产、产后出血、胎儿窘迫、新生儿窒息等不良妊娠结局的发生率均显著低于对照组,其差异有统计学意义( P ＜0 .05) .用药期间观察组不良反应总发生率为39 .22%(20／51) ,与对照组的35 .29%(18／51)比较差异无统计学意义( P ＞0 .05) ,且两组不良反应均较轻微,经对症处理自行好转,不影响后续治疗.[结论]妊娠期高血压疾病应用拉贝洛尔联合依诺肝素治疗,能够显著降低患者血压及24h尿蛋白量,降低不良妊娠结局发生率,且安全性高,值得临床推广应用.“,”To investigate the effects of labelore combined with enoxaparin on blood pressure level and its safety in patients with hypertensive diseases in pregnancy .[M ethods] One hundred and two pa‐tients with gestational hypertension admitted to our hospital from June 2017 to June 2018 were randomly divid‐ed into two groups .T he control group was treated with oral labetalol tablets ,and the study group was treated with labetalol combined with enoxaparin .T he clinical therapeutic effect ,blood pressure level ,24 h urinary protein level ,blood lipid level before and after treatment ,and the incidence of adverse reactions and severe ad‐verse pregnancy outcomes were compared between the two groups .[Results]T he total effective rate was 94 . 1%(48／51 ) in the observation group ,w hich was significantly higher than 78 .4%(40／51 ) in the control group .T he difference was statistically significant (χ2 ＝7 .318 ,P ＜0 .05).Before treatment ,there was no sig‐nificant difference in blood pressure and 24‐hour urinary protein between the two groups ( P ＞0 .05 ) ;after treatment ,the above indicators in both groups decreased significantly compared with before treatment ( P ＜0 .05) ,and the observation group decreased more significantly ( P ＜0 .05).Before treatment ,there was no significant difference in blood lipid levels between the two groups ( P ＞0 .05 ) ;after treatment ,the levels of LDL‐C ,TC and TG in the two groups were significantly lower than those before treatment ,and the levels of HDL‐C were significantly higher than those before treatment ,and the observation group was significantly bet‐ter than those before treatment .T he control group ( P ＜0 .05).Compared with the control group ,the inci‐dence of adverse pregnancy outcomes such as premature delivery ,postpartum hemorrhage ,fetal distress and neonatal asphyxia in the observation group was significantly lower than that in the control group ,and the difference was statistically significant ( P ＜0 .05).T he total incidence of adverse reactions was 39 .22%(20／51) in the observation group and 35 .29%(18／51) in the control group .T here was no significant difference be‐tween the two groups ( P ＞0 .05).T he adverse reactions in the two groups were mild and improved by symp‐tomatic treatment without affecting the follow‐up treatment .[Conclusion]Labellol combined with enoxaparin in the treatment of pregnancy‐induced hypertension can significantly reduce blood pressure and 24‐hour urinary protein levels ,reduce the incidence of adverse pregnancy outcomes ,and has high safety ,w hich is worthy of clinical application .